NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Scribe Therapeutics Inc. (SCTX) Stock Analysis

Scribe Therapeutics Inc. (SCTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SCTX

$28.67

−$2.14 (−6.95%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SCTX with… →

SCTX Key Statistics

As of Sep 4, 2026
Trading
Open
$30.21
Previous Close
$30.81
Day's Range
28.50–31.45
52-Week Range
17.31–39.60
Volume
147.90K
Valuation
Market Cap
$542.77M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
16.30
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.84
Financials (FY)
Revenue (FY)
$51.17M+86.68%
Net Income (FY)
−$21.81M
Profit marginThe share of revenue left as profit after all costs and taxes.
−97.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
18.93M
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
229.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SCTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$51.17M−$21.81M−42.6%
2024$27.41M−$47.79M−174.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$51.17M—−$26.07M−$21.81M−42.6%
2024$27.41M—−$42.83M−$47.79M−174.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SCTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricSCTXBiotechnology medianvs median
P/S ratio16.3015.267% above
Profit margin−97.00%0.00%97.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Scribe Therapeutics Inc. (SCTX) carries a market capitalisation of $542.77M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 82.

SCTX last closed at $28.67 on September 4, 2026. That is −$2.14 (−6.95%) against the previous close. The 52-week range on file runs from $17.31 to $39.60. The latest close sits 65.63% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $51.17M. That is +86.68% against the prior fiscal year, when revenue was $27.41M. The same year closed with a net loss of $21.81M. The reported profit margin is −97%. That is 97 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.84.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 16.3 times revenue. On price-to-sales that is 6.78% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Growth & Income

No dividend is on file for SCTX.

2026 is still running; the price is +32.42% year to date.

Peer Comparison

Scribe Therapeutics Inc. (SCTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Scribe Therapeutics Inc. SCTX $542.77M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Scribe Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Scribe Therapeutics Inc.

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

Visit website →